Asset Management One Boosts Stake in Vertex Pharmaceuticals

Institutional investor increases position in biotech company by 2.2% in Q4

Apr. 18, 2026 at 7:22am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, interlocking metal gears and machinery in shades of steel grey, bronze, and silver, conceptually representing the institutional investment and financial infrastructure powering the biotech industry.Institutional investors continue to back Vertex Pharmaceuticals as the biotech firm expands its drug pipeline and solidifies its market position.Boston Today

Asset Management One Co. Ltd. increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.2% during the fourth quarter, according to a recent SEC filing. The institutional investor now owns 150,106 shares of the pharmaceutical company's stock, valued at around $69 million.

Why it matters

Vertex Pharmaceuticals is a leading biotech firm focused on developing treatments for serious diseases like cystic fibrosis. This increase in ownership by a major institutional investor signals continued confidence in the company's pipeline and future growth prospects.

The details

According to the filing, Asset Management One purchased an additional 3,242 shares of Vertex Pharmaceuticals during the fourth quarter, bringing its total position to 150,106 shares. This represents about 0.06% of the company's outstanding stock. The move comes as Vertex Pharmaceuticals' share price has fluctuated between $362.50 and $510.77 over the past 52 weeks.

  • The filing covers the fourth quarter of 2025.
  • Asset Management One increased its stake in Vertex during this time period.

The players

Asset Management One Co. Ltd.

A major institutional investor that manages over $1 trillion in assets globally.

Vertex Pharmaceuticals Incorporated

A Boston-based biotech company focused on developing treatments for serious diseases like cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

This increase in ownership by a prominent institutional investor underscores the market's continued confidence in Vertex Pharmaceuticals' ability to drive growth through its innovative drug pipeline and solidify its position as a leader in the biotech industry.